259 related articles for article (PubMed ID: 34657149)
21. Mechanisms of suppression of cell growth by dual inhibition of ALK and MEK in ALK-positive non-small cell lung cancer.
Shrestha N; Nimick M; Dass P; Rosengren RJ; Ashton JC
Sci Rep; 2019 Dec; 9(1):18842. PubMed ID: 31827192
[TBL] [Abstract][Full Text] [Related]
22. Crizotinib (PF-2341066) induces apoptosis due to downregulation of pSTAT3 and BCL-2 family proteins in NPM-ALK(+) anaplastic large cell lymphoma.
Hamedani FS; Cinar M; Mo Z; Cervania MA; Amin HM; Alkan S
Leuk Res; 2014 Apr; 38(4):503-8. PubMed ID: 24486291
[TBL] [Abstract][Full Text] [Related]
23. SHP2 Inhibition with TNO155 Increases Efficacy and Overcomes Resistance of ALK Inhibitors in Neuroblastoma.
Valencia-Sama I; Kee L; Christopher G; Ohh M; Layeghifard M; Shlien A; Hayes MN; Irwin MS
Cancer Res Commun; 2023 Dec; 3(12):2608-2622. PubMed ID: 38032104
[TBL] [Abstract][Full Text] [Related]
24. Pharmacological inhibitors of anaplastic lymphoma kinase (ALK) induce immunogenic cell death through on-target effects.
Petrazzuolo A; Perez-Lanzon M; Martins I; Liu P; Kepp O; Minard-Colin V; Maiuri MC; Kroemer G
Cell Death Dis; 2021 Jul; 12(8):713. PubMed ID: 34272360
[TBL] [Abstract][Full Text] [Related]
25. ALK kinase domain mutations in primary anaplastic large cell lymphoma: consequences on NPM-ALK activity and sensitivity to tyrosine kinase inhibitors.
Lovisa F; Cozza G; Cristiani A; Cuzzolin A; Albiero A; Mussolin L; Pillon M; Moro S; Basso G; Rosolen A; Bonvini P
PLoS One; 2015; 10(4):e0121378. PubMed ID: 25874976
[TBL] [Abstract][Full Text] [Related]
26. The tyrosine phosphatase Shp2 interacts with NPM-ALK and regulates anaplastic lymphoma cell growth and migration.
Voena C; Conte C; Ambrogio C; Boeri Erba E; Boccalatte F; Mohammed S; Jensen ON; Palestro G; Inghirami G; Chiarle R
Cancer Res; 2007 May; 67(9):4278-86. PubMed ID: 17483340
[TBL] [Abstract][Full Text] [Related]
27. Oncogenic role of miR-155 in anaplastic large cell lymphoma lacking the t(2;5) translocation.
Merkel O; Hamacher F; Griessl R; Grabner L; Schiefer AI; Prutsch N; Baer C; Egger G; Schlederer M; Krenn PW; Hartmann TN; Simonitsch-Klupp I; Plass C; Staber PB; Moriggl R; Turner SD; Greil R; Kenner L
J Pathol; 2015 Aug; 236(4):445-56. PubMed ID: 25820993
[TBL] [Abstract][Full Text] [Related]
28. Treatment of Relapsed and Refractory ALK-Positive Anaplastic Large Cell Lymphoma With ALK-Specific Tyrosine Kinase Inhibitor in Children: A Case Series.
Shen D; Song H; Zhang J; Liao C; Wang Y; Fang M; Tang Y
J Pediatr Hematol Oncol; 2022 Jan; 44(1):e1-e4. PubMed ID: 33661174
[TBL] [Abstract][Full Text] [Related]
29. Reversal of microRNA-150 silencing disadvantages crizotinib-resistant NPM-ALK(+) cell growth.
Hoareau-Aveilla C; Valentin T; Daugrois C; Quelen C; Mitou G; Quentin S; Jia J; Spicuglia S; Ferrier P; Ceccon M; Giuriato S; Gambacorti-Passerini C; Brousset P; Lamant L; Meggetto F
J Clin Invest; 2015 Sep; 125(9):3505-18. PubMed ID: 26258416
[TBL] [Abstract][Full Text] [Related]
30. The ALK inhibitor ASP3026 eradicates NPM-ALK⁺ T-cell anaplastic large-cell lymphoma in vitro and in a systemic xenograft lymphoma model.
George SK; Vishwamitra D; Manshouri R; Shi P; Amin HM
Oncotarget; 2014 Jul; 5(14):5750-63. PubMed ID: 25026277
[TBL] [Abstract][Full Text] [Related]
31. STAT1 is phosphorylated and downregulated by the oncogenic tyrosine kinase NPM-ALK in ALK-positive anaplastic large-cell lymphoma.
Wu C; Molavi O; Zhang H; Gupta N; Alshareef A; Bone KM; Gopal K; Wu F; Lewis JT; Douglas DN; Kneteman NM; Lai R
Blood; 2015 Jul; 126(3):336-45. PubMed ID: 25921060
[TBL] [Abstract][Full Text] [Related]
32. Treatment Sequencing in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer in Japan: A Real-World Observational Study.
Goto Y; Yamamoto N; Masters ET; Kikkawa H; Mardekian J; Wiltshire R; Togo K; Ohe Y
Adv Ther; 2020 Jul; 37(7):3311-3323. PubMed ID: 32472430
[TBL] [Abstract][Full Text] [Related]
33. Patient-derived xenograft models of ALK+ ALCL reveal preclinical promise for therapy with brigatinib.
Prokoph N; Matthews JD; Trigg RM; Montes-Mojarro IA; Burke GAA; Fend F; Merkel O; Kenner L; Geoerger B; Johnston R; Murray MJ; Riguad C; Brugières L; Turner SD
Br J Haematol; 2023 Sep; 202(5):985-994. PubMed ID: 37357529
[TBL] [Abstract][Full Text] [Related]
34. Concomitant resistance mechanisms to multiple tyrosine kinase inhibitors in ALK-positive non-small cell lung cancer.
Yu Y; Ou Q; Wu X; Bao H; Ding Y; Shao YW; Lu S
Lung Cancer; 2019 Jan; 127():19-24. PubMed ID: 30642546
[TBL] [Abstract][Full Text] [Related]
35. Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer.
Yamaguchi N; Lucena-Araujo AR; Nakayama S; de Figueiredo-Pontes LL; Gonzalez DA; Yasuda H; Kobayashi S; Costa DB
Lung Cancer; 2014 Jan; 83(1):37-43. PubMed ID: 24199682
[TBL] [Abstract][Full Text] [Related]
36. Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing.
Lin YT; Chiang CL; Hung JY; Lee MH; Su WC; Wu SY; Wei YF; Lee KY; Tseng YH; Su J; Chung HP; Lin CB; Ku WH; Chiang TS; Chiu CH; Shih JY
Eur J Cancer; 2021 Oct; 156():1-11. PubMed ID: 34392186
[TBL] [Abstract][Full Text] [Related]
37. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.
Mossé YP; Lim MS; Voss SD; Wilner K; Ruffner K; Laliberte J; Rolland D; Balis FM; Maris JM; Weigel BJ; Ingle AM; Ahern C; Adamson PC; Blaney SM
Lancet Oncol; 2013 May; 14(6):472-80. PubMed ID: 23598171
[TBL] [Abstract][Full Text] [Related]
38. Phosphoproteome and gene expression profiling of ALK inhibition in neuroblastoma cell lines reveals conserved oncogenic pathways.
Van den Eynden J; Umapathy G; Ashouri A; Cervantes-Madrid D; Szydzik J; Ruuth K; Koster J; Larsson E; Guan J; Palmer RH; Hallberg B
Sci Signal; 2018 Nov; 11(557):. PubMed ID: 30459281
[TBL] [Abstract][Full Text] [Related]
39. The novel ALK inhibitor ZX-29 induces apoptosis through inhibiting ALK and inducing ROS-mediated endoplasmic reticulum stress in Karpas299 cells.
Zhou X; Zhang X; Wu Z; Xu X; Guo M; Zhai X; Zuo D; Wu Y
J Biochem Mol Toxicol; 2021 Mar; 35(3):e22666. PubMed ID: 33140567
[TBL] [Abstract][Full Text] [Related]
40. Differential regulation of FGFR3 by PTPN1 and PTPN2.
St-Germain JR; Taylor P; Zhang W; Li Z; Ketela T; Moffat J; Neel BG; Trudel S; Moran MF
Proteomics; 2015 Jan; 15(2-3):419-33. PubMed ID: 25311528
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]